The European Federation for Medicinal Chemistry (EFMC) Best Practice Initiative: Validating Chemical Probes
暂无分享,去创建一个
Stéphanie M. Guéret | G. Sbardella | D. Finsinger | Jean Quancard | J. Messinger | Ingo V. Hartung | S. Laufer | Brian Cox | H. Koolman | I. Hartung
[1] W. Liu,et al. Covalent Inhibition in Drug Discovery , 2019, ChemMedChem.
[2] R. Hersperger,et al. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient , 2019, Nature Chemical Biology.
[3] Julian Blagg,et al. Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology , 2017, Cancer cell.
[4] H. Waldmann,et al. Small-Molecule Target Engagement in Cells. , 2016, Cell chemical biology.
[5] Andrew Pannifer,et al. The importance of triaging in determining the quality of output from high-throughput screening. , 2015, Future medicinal chemistry.
[6] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[7] Ramzi F Sweis,et al. Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry. , 2015, ACS medicinal chemistry letters.
[8] Mark E Bunnage,et al. Target validation using chemical probes. , 2013, Nature chemical biology.
[9] Ian Collins,et al. Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.
[10] James Inglese,et al. Apparent activity in high-throughput screening: origins of compound-dependent assay interference. , 2010, Current opinion in chemical biology.
[11] Stephen V Frye,et al. The art of the chemical probe. , 2010, Nature chemical biology.